AMG386 plus PLD + Placebo plus PLD
Phase 3Terminated 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Fallopian Tube Cancer
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
Trial Timeline
Apr 18, 2011 → Apr 19, 2017
NCT ID
NCT01281254About AMG386 plus PLD + Placebo plus PLD
AMG386 plus PLD + Placebo plus PLD is a phase 3 stage product being developed by Amgen for Fallopian Tube Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT01281254. Target conditions include Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01281254 | Phase 3 | Terminated |
Competing Products
20 competing products in Fallopian Tube Cancer